Christopher James Stevens' Stock Transactions in Rocket Pharmaceuticals, Inc.

Christopher James Stevens, Chief Operating Officer of Rocket Pharmaceuticals, Inc., reported significant stock transactions on August 4, 2025. Stevens acquired 554,071 stock options with an exercise price of $3.07 per share, which will vest in three equal parts starting August 4, 2026, and continuing quarterly over the next two years. Additionally, Stevens acquired 407,166 shares of common stock through Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis. These RSUs will also vest in three equal parts starting August 4, 2026, with the remaining shares vesting quarterly over the following two years. Both transactions are subject to Stevens' continued employment with the company.